Preliminary Schedule

Rm. TBD CAR T and Related Immune Effector Cell Therapies Workshop
  Clinical Long Term Follow-Up
  10:10 a.m.-12 p.m.

Now that CAR T cells have been in clinical use for over 5 years, this session will focus on the clinical results and longer-term follow up of CAR T cell studies in hematologic malignancies, on the consensus grading systems that have emerged as CAR T cells enter general practice and there are more and more clinical studies, and on how clinical centers manage the administration and collection of long-term follow-up data required by regulatory bodies.

Cameron Turtle, MBBS, PhD, Adult NHL

Shannon Maude, MD, PhD, Pediatric ALL

Jim Kochenderfer, MD, MM/BCMA

Sattva Neelapu, MD, ASBMT CRS grading and ASBMT neurotox grading

Sarah Nikiforow, MD, PhD, Long term follow-up program development

Matt Frigault, MD, Requirements to establish a phase 1 program

  Novel Engineering and Gene Editing
  1-3:10 p.m.

This session will focus on the scientific innovation as well as the safety and regulatory aspects of next-generation genetic engineering strategies that are in development that will enable complex strategies to target novel antigens not amenable to standard autologous CAR T cell therapies or to enable allogeneic cellular products.

Wendell Lim, PhD, Syn–notc

Justin Eyquem, PhD, TRAC locus targeting

Saar Gill, MD, PhD, CD33 edit and CD33 CAR-T cells

J. Keith Joung, MD, PhD, Measuring off-target effects of editing – Regulatory aspects of QC/release in gene edited products

  Beyond Autologous CAR-T Cells for Cancer
  3:30-6 p.m.

CAR T cells are in wide clinical use in B cell cancers as autologous cellular products that have been transduced to express a single transgene. This session will focus on innovations with alternative cellular products and indications, such as allogeneic NK cells, stem cells, and potential uses of engineered cell therapies on non-cancer indications.

Katy Rezvani, MD, PhD, NK-CARs

Michel Sadelain, MD, PhD, iPSC-derived IEC

Marcela Maus, MD, PhD, Treg CARs

Mike Milone, MD, PhD, Non-cancer – pemphigus

Cyril Konto MD, VP of Clinical Development at Allogene Therapeutics

Rm. TBD Gene Editing Workshop
 

The Gene Editing workshop provides an overview of current gene editing technologies and approaches, emerging uses and applications, with sessions highlighting junior investigators and clinical gene editing programs.

  10-10:20 a.m.

Introduction to Gene Editing led by Morgan Maeder, PhD.

  10:20 a.m.-12 p.m.

NIH Genome Editing Consortium Grant Recipients

The National Institutes of Health recently awarded its first grants through the Somatic Cell Genome Editing program. In this session we will hear from some of these initial awardees.

Shaoqin Gong, PhD

Guangping Gao, PhD

Shengdar Tsai, PhD

Erik Sontheimer, PhD

  12-1 p.m. Lunch
  1-2 p.m.

Corporate Review I

A series of presentations from some of the leading companies in gene editing, describing their pre-clinical and clinical programs.

Shawdee Eshighi, PhD, Caribou Biosciences

Leonela Amoasii, PhD, Exonics Therapeutics

Derek Jantz, PhD, Precision BioSciences

Charlie Albright, PhD, Editas Medicine

Tony Ho, MD, CRISPR Therapeutics

  2-3 p.m.

NIH Genome Editing Consortium Grant Recipients Continued

The National Institutes of Health recently awarded its first grants through the Somatic Cell Genome Editing program. In this session we will hear from some of these initial awardees.

Aravind Asokan, PhD

Betty Poon, PhD

  3-3:30 p.m. Coffee Break
  3:30-5 p.m.

Junior Investigator Session

Gene editing is a dynamic area of research, attracting many new investigators. This session highlights the work of some of the outstanding junior investigators in the field.

Pietro Genovese, PhD

Ben Kleinstiver, PhD

Thomas Gaj, PhD

Prashant Mali, PhD

Pinar Akcakaya, PhD

Jennifer Adair, PhD

  5-6 p.m.

Corporate Review II

A series of presentations from some of the leading companies in gene editing, describing their pre-clinical and clinical programs.

Edward Rebar, PhD, Sangamo Therapeutics

Julianne Smith, PhD, Cellectis

Philip Gregory, DPhil, bluebird bio

Andy Scharenberg, MD, Casebia Theapeutics

Fred Chereau, MBA, LogicBio

Sean Burns, Intellia Therapeutics

Rm. TBD Pre-Approval Commercialization Workshop
  The Pre-Approval Commercialization Workshop covers industry perspectives on CMC Challenges for cell and gene modified cell therapy products, updates from global regulatory bodies, manufacturing challenges in late phase development of gene therapy products, and discussions on the difficulties in commercializing AAV product candidates.
  10-10:30 a.m. Patient Perspective Keynote
  10:30 a.m.-12 p.m. Industry Perspective on CMC Challenges for Cell and Gene Modified Cell Therapy Products
  12-1 p.m. Lunch
  1-2:30 p.m.

Global Regulatory Update: Outlook in 2019 – Policy Approaches and Considerations in Gene Therapy

Peter Marks, Director, Center for Biologics Evaluation and Research

Martina Schüssler-Lenz, Chair, EMA Committee for Advanced Therapies

  2:30-3 p.m. Coffee Break
  3-4:30 p.m. Manufacturing Challenges During Late Phase Development of Gene Therapy Products
  4:30-6 p.m. Hindrance to Commercializing AAV Product Candidates
Rm. TBD Post-Approval Commercialization Workshop
  New for 2019, the Post-Approval Commercialization Workshop will include sessions on patient focused drug development; post-approval change management and overall impact on commercialization; and pricing, reimbursement, and payment models for gene therapies.
  10-10:30 a.m. Keynote Speaker
  10:30 a.m.-12 p.m. The Role of the Patient Panel
  12-1 p.m. Lunch
  1-2:30 p.m. Post-Approval Change Management and Overall Impact
  3-6 p.m. Value and Reimbursement
International Ballroom East Bio Industry Symposium
  Co-Chairs: Gwendolyn Binder, PhD and Marcela Maus, MD, PhD
  8-10 a.m. Entering the Post-RAC Era Charting the Course of Cell & Gene Therapy Drug Development for the Future
International Ballroom West International Symposium
  Co-Chairs: Juan A. Bueren, PhD and Claire Booth, MBBS, PhD
  8-10 a.m. Innovation in First Time in Human Study Clinical Studies
Jefferson Government Relations Symposium
  Co-Chairs: Francesca Cook, MPH and Tim Hunt, JD
  8-10 a.m. Pricing, Access, and Value of Gene Therapies: What Are the Real-World Challenges and Solutions?
Lincoln Nanoagents & Synthetic Formulations Symposium
  Co-Chairs: Assem Ziady, PhD and Chantal Pichon, PhD
  8-10 a.m. Non-Viral Vectors and Immunity
Georgetown Respiratory & GI Tract Symposium
  Co-Chairs: Maria P. Limberis, PhD and Patrick L. Sinn, PhD
  8-10 a.m. Novel Strategies for Lung and GI Tract-directed Genetic Therapies
  Coffee Break
  Cup Sleeve Sponsorship Still Available!
  10-10:30 a.m. Complimentary coffee available outside session rooms and in the exhibit hall.
Exhibit Hall Exhibit Hall Open
  See the full list of exhibitors and the Exhibit Hall floorplan
  10 a.m.-6 p.m. For the first time, the Exhibit Hall will be open for the vast majority of the Annual Meeting's operating hours.
Various Meeting Rooms Oral Abstract Session I
  Abstracts available on April 15
  10:30 a.m.-12 p.m. Approximately 25 percent of accepted abstracts are scheduled as oral abstract presentations. Oral abstract presentations are formal PowerPoint presentations given during two-hour, simultaneous oral abstract sessions. A total of 8 abstracts are presented in each session. Presentations are 10 minutes in length followed by a 5 minute Q&A.
  Lunch Break
  Lunch Not Provided
  12-1:30 p.m. Download the ASGCT app to find great local lunch options nearby!
International Ballroom East Adoptive T-Cell Therapy Education Session
  Co-Chairs: Catherine M. Bollard, MD and Daniel J. Powell, PhD
  1:30-3 p.m. Topics and speaker information coming soon!
International Ballroom West AAV Vectors Education Session
  Co-Chairs: TBD
  1:30-3 p.m. Topics and speaker information coming soon!
Jefferson Modalities of Genome Editing Education Session
  Co-Chairs: Thomas Wechsler, PhD and John Tisdale, MD
  1:30-3 p.m. Topics and speaker information coming soon!
Lincoln Oncolytics Education Session
  Co-Chairs: Tanja M. Meyer, PhD and TBD
  1:30-3 p.m. Topics and speaker information coming soon!
Georgetown NK Cells Versus iNKT Cells Education Session
  Co-Chairs: Leonid S. Metelitsa, MD, PhD and Katy Rezvani, MD, PhD
  1:30-3 p.m. Topics and speaker information coming soon!
Monroe Induced Pluripotent Stem Cells Education Session
  Co-Chairs: Blythe Sather, PhD and Jizhong Zou, PhD
  1:30-3 p.m. Topics and speaker information coming soon!
  Coffee Break
  Cup Sleeve Sponsorship Still Available!
  3-3:45 p.m. Complimentary coffee available outside session rooms and in the exhibit hall.
Various Meeting Rooms Oral Abstract Session II
  Abstracts available on April 15
  3:45-5:30 p.m. Approximately 25 percent of accepted abstracts are scheduled as oral abstract presentations. Oral abstract presentations are formal PowerPoint presentations given during two-hour, simultaneous oral abstract sessions. A total of 8 abstracts are presented in each session. Presentations are 10 minutes in length followed by a 5 minute Q&A.
Exhibit Hall Tools and Technologies Forum
  Debuting Innovative Products!
  4-6 p.m. The Tools and Technologies Forum provides exhibitors the opportunity to present their products, services, tools, and technologies in 15-minute-long presentations.
Exhibit Hall Welcome Reception & Poster Session I
  Best in Class Research
  5-6 p.m. Seventy-five percent of all abstracts presented at the Annual Meeting occur during one of three poster sessions. Poster sessions allow the presenter to illustrate the abstract on a poster board and discuss the abstract with attendees in-person.

The first poster session of the 22nd Annual Meeting is paired with the opening night Welcome Reception for all attendees.
Jefferson Industry Symposium
  GE Healthcare
  6-7:30 p.m. This content of this sponsored symposium will be determined by the sponsor and presented independent of ASGCT.
TBD Reconnection & Mentoring Event
  6-8 p.m. Participants in ASGCT's mentorship program are invited to a private networking event to reconnect with colleagues and make new contacts.
International Ballroom East Cancer Scientific Symposium
  Co-Chairs: Robert E. Sobol, MD and Giedre Krenciute, PhD
  8-10 a.m. Towards the Holy Grail of Cancer Gene Therapies: Universal Cells, Targeted Vectors and Solid Tumor CART Efficacy
International Ballroom West Genome Editing Scientific Symposium
  Co-Chairs: Morgan L. Maeder, PhD and TBD
  8-10 a.m. Gene Editing: From Platform Engineering to Assessing Impact of Innate and Adaptive Responses
Jefferson Viral Gene Transfer Vectors Scientific Symposium
  Co-Chairs: Coy Heldermon, MD, PhD and Ko Mitani, PhD
  8-10 a.m. Vector Development, Clinical Implementation, and Corporate Connections
Lincoln Translational Science and Product Development Scientific Symposium
  Co-Chairs: Eduard Ayuso, DVM, PhD and Isabelle Riviere, PhD
  8-10 a.m. Evaluating Gene & Cell Therapy Product Candidates
Georgetown RNA Therapeutics Education Session
  Co-Chairs: Millicent Sullivan, PhD and Jonathan Finn, PhD
  8-10 a.m. “How-to” – Design, Delivery, and Application of RNA Therapeutics
Monroe Cardiovascular Scientific Symposium
  Co-Chairs: Costanza Emanueli, PhD, FAHA and Manfred Boehm, MD
  8-10 a.m. Beyond Cell Therapy: Extracellular vs. Multicellular Cardiovascular Regenerative Approaches
Exhibit Hall Coffee Social and Oral Poster Session
  Abstracts available on April 15
  10-10:45 a.m.  
International Ballroom George Stamatoyannopoulos Memorial Lecture & Presentation of the Excellence in Research & Sonia Skarlatos Public Service Award Presentation
  ASGCT President Michele Calos, PhD and Michel Sadelain, M.D., Ph.D.
  10:45-11 a.m. Presentation of Excellence in Research & Sonia Skarlatos Public Service Awards by ASGCT President Michele Calos, PhD.
  11 a.m.-12 p.m. Michel Sadelain, M.D., Ph.D. delivers the George Stamatoyannopoulos Memorial Lecture.

Sadelain’s research focuses on human cell engineering and cell therapy to treat cancer and hereditary blood disorders. His laboratory has made several seminal contributions to the field of chimeric antigen receptors (CARs), from their conceptualization and optimization to their clinical translation for cancer immunotherapy. His group was the first to publish dramatic molecular remissions in patients with chemorefractory acute lymphoblastic leukemia following treatment with autologous CD19-targeted T cells.
  Lunch Break
  Lunch Not Provided
  12-1:30 p.m. Download the ASGCT app to find great local lunch options nearby!
Monroe Industry Lunch Symposium
  Miltenyi Biotec
  12-1:30 p.m. This content of this sponsored symposium will be determined by the sponsor and presented independent of ASGCT.
Lincoln Industry Lunch Symposium
  TerumoBCT
  12-1:30 p.m. This content of this sponsored symposium will be determined by the sponsor and presented independent of ASGCT.
Jefferson Industry Lunch Symposium
  Retrogenix
  12-1:30 p.m. This content of this sponsored symposium will be determined by the sponsor and presented independent of ASGCT.
Georgetown Industry Lunch Symposium
  Maxcyte
  12-1:30 p.m. This content of this sponsored symposium will be determined by the sponsor and presented independent of ASGCT.
International Ballroom Outstanding New Investigator Symposium
  Awardees TBA
  1:30-3 p.m. The Outstanding New Investigator awardees detail their research in this plenary session.
Exhibit Hall Coffee Social
  Cup Sleeve Sponsorship Still Available!
  1:30-3 p.m. Complimentary coffee available outside session rooms and in the exhibit hall.
Various Meeting Rooms Oral Abstract Session III
  Abstracts available on April 15
  3:45-5:15 p.m. Approximately 25 percent of accepted abstracts are scheduled as oral abstract presentations. Oral abstract presentations are formal PowerPoint presentations given during two-hour, simultaneous oral abstract sessions. A total of 8 abstracts are presented in each session. Presentations are 10 minutes in length followed by a 5 minute Q&A.
Exhibit Hall Tools and Technologies Forum
  Debuting Innovative Products!
  4-6 p.m. The Tools and Technologies Forum provides exhibitors the opportunity to present their products, services, tools, and technologies in 15-minute-long presentations.
Exhibit Hall Networking Reception & Poster Session II
  Best in Class Research
  5-6 p.m. Seventy-five percent of all abstracts presented at the Annual Meeting occur during one of three poster sessions. Poster sessions allow the presenter to illustrate the abstract on a poster board and discuss the abstract with attendees in-person.
Jefferson Industry Symposium
  Pall Biotech
  6-7:30 p.m. This content of this sponsored symposium will be determined by the sponsor and presented independent of ASGCT.
TBD New Member Receptions
  Join ASGCT for refreshments and networking!
  6-7 p.m. Members new to ASGCT are invited for refreshments and conversation as a welcome to the Society.
International Ballroom East Immune Responses Scientific Symposium
  Co-Chairs: Maria Castro, PhD and Irina Balyasnikova, PhD
  8-10 a.m. Basic and Translational Aspects of Immunology and Gene and Cell Therapy
International Ballroom West Neurologic & Ophthalmic Scientific Symposium
  Co-Chairs: Caroline E. Bass, PhD and David J. Segal, PhD
  8-10 a.m. Genome Editing in the Retina and CNS
Jefferson Ethics Scientific Symposium
  Co-Chairs: Pilar N. Ossorio, PhD, JD and Bruce E. Torbett, PhD, MSPH
  8-10 a.m. Right to Try or Wrong to Try?
Lincoln Physical Delivery, Therapeutics & Vector Development Scientific Symposium
  Co-Chairs:    Dexi Liu, PhD and Lauren Woodard, PhD
  8-10 a.m. Translating non-viral Gene Delivery to Human Therapeutics
Georgetown Stem Cell Scientific Symposium
  Co-Chairs: M. Graca D. Almeida-Porada, MD, PhD and Eirini P. Papapetrou, MD, PhD
  8-10 a.m. Genetic Modification of Stem Cells
Monroe Infectious Diseases and Vaccines Scientific Symposium
  Co-Chairs: Claire Evans, PhD and Matti Sallberg, PhD, DDS
  8-10 a.m. Prophylactic and Therapeutic Antibodies against Infectious Diseases
Exhibit Hall Coffee Social and Oral Poster Session
  Abstracts available on April 15
  10-10:45 a.m.  
International Ballroom Outstanding Achievement Award Lecture
  Awardee TBA
  10:45-11:45 The Outstanding Achievement Award honoree profiles their career-long journey in the latest installment of this annual landmark lecture series.
  Lunch Break
  Lunch Not Provided
  11:45 a.m. - 1:15 p.m. Download the ASGCT app to find great local lunch options nearby!
Jefferson Industry Lunch Symposium
  Sarepta Therapeutics
  11:45 a.m. - 1:15 p.m. This content of this sponsored symposium will be determined by the sponsor and presented independent of ASGCT.
International Ballroom Presidential Symposium & Presentation of the Top Abstracts
  ASGCT President Michele Calos, PhD, and George M. Church, PhD
  1:15-2:15 p.m. George M. Church, PhD delivers the Presidential Symposium Lecture.

Church is professor of genetics at Harvard Medical School, a founding member of the Wyss Institute, and director of PersonalGenomes.org, the world’s only open-access information on human genomic, environmental, and trait data. He developed the first methods for the first genome sequence & dramatic cost reductions since then (down from $3 billion to $600).
  2:15-3:15 p.m. The top-rated abstracts from all specialties are presented during this all-meeting plenary session.
Exhibit Hall Coffee Social
  Cup Sleeve Sponsorship Still Available!
  1:30-3 p.m. Complimentary coffee available outside session rooms and in the exhibit hall.
Various Meeting Rooms Oral Abstract Session IV
  Abstract Submission open through January 16
  4-5:45 p.m. Approximately 25 percent of accepted abstracts are scheduled as oral abstract presentations. Oral abstract presentations are formal PowerPoint presentations given during two-hour, simultaneous oral abstract sessions. A total of 8 abstracts are presented in each session. Presentations are 10 minutes in length followed by a 5 minute Q&A.
Exhibit Hall Tools and Technologies Forum
  Debuting Innovative Products!
  4-6 p.m. The Tools and Technologies Forum provides exhibitors the opportunity to present their products, services, tools, and technologies in 15-minute-long presentations.
Exhibit Hall Poster Session III
  Best in Class Research
  5-6 p.m. Seventy-five percent of all abstracts presented at the Annual Meeting occur during one of three poster sessions. Poster sessions allow the presenter to illustrate the abstract on a poster board and discuss the abstract with attendees in-person.
Jefferson Industry Symposium
  Audentes Therapeutics
  6-7:30 p.m. This content of this sponsored symposium will be determined by the sponsor and presented independent of ASGCT.
Smithsonian National Portrait Gallery Closing Night Reception
  Add to your Annual Meeting registration for just $25!
  8-11 p.m. Transportation from the Washington Hilton will be provided by ASGCT, but reception attendance is limited to 1,400 so sign up early!
  Coffee Social
  Cup Sleeve Sponsorship Still Available!
  7:30-8 a.m. Open the final day of the Annual Meeting with a cup of coffee and an opportunity to catch up.
International Ballroom East Genetic and Metabolic Diseases Scientific Symposium
  Co-Chairs: Denise Sabatino, PhD and Randy Chandler, PhD, MB
  8-10 a.m. Applications of Gene and Cell Therapy Technologies for Metabolic Diseases
International Ballroom West Hematologic and Immunologic Scientific Symposium
  Co-Chairs: Jennifer E. Adair, PhD and Jennifer L. Gori, PhD
  8-10 a.m. Fitness by Design: Engineering Homing, Persistence and Potency in Cell Therapies
Jefferson Clinical Trials and Regulatory Affairs Scientific Symposium
  Co-Chairs: Adora Ndu, PharmD, JD and Richard Morgan, PhD
  8-10 a.m. Getting to the Finish Line: Market Success
Lincoln Commercialization Symposium
  Co-Chairs: Sarah Pitluck, MSc and Katy Spink, PhD
  8-10 a.m. Commercializing Gene and Cell Therapies – Planning for Post-Approval Success and Pitfalls to Avoid
Georgetown Musculo-Skeletal Scientific Symposium
  Co-Chairs: Joel R. Chamberlain, PhD and Niclas E. Bengtsson, PhD
  8-10 a.m. Gene Editing and Gene Modulation for Musculoskeletal Disease
Monroe Oligonucleotide and RNAi Therapeutics Scientific Symposium
  Co-Chairs: Michelle L. Hastings, PhD and Janaiah Kota, PhD
  8-10 a.m. Clinical Status of Oligonucleotide-based Drugs
Various Meeting Rooms Oral Abstract Session V
  Abstracts available on April 15
  10:15 a.m. - 12:15 p.m. Approximately 25 percent of accepted abstracts are scheduled as oral abstract presentations. Oral abstract presentations are formal PowerPoint presentations given during two-hour, simultaneous oral abstract sessions. A total of 8 abstracts are presented in each session. Presentations are 10 minutes in length followed by a 5 minute Q&A.